{
    "clinical_study": {
        "@rank": "31862", 
        "arm_group": [
            {
                "arm_group_label": "glucosamine sulfate /chondroitin sulfate capsule", 
                "arm_group_type": "Experimental", 
                "description": "500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily."
            }, 
            {
                "arm_group_label": "glucosamine sulfate /chondroitin sulfate - sachet", 
                "arm_group_type": "Experimental", 
                "description": "1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily."
            }, 
            {
                "arm_group_label": "Cosamin DS\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether 500 mg Glucosamine Sulfate / 400 mg\n      Chondroitin Sulfate Capsules and 1500 mg Glucosamine Sulfate / 1200 mg Chondroitin Sulfate\n      Sachet is effective and safe compared Cosamin DS \u00ae Capsule in Treatment of Knee\n      Osteoarthritis."
        }, 
        "brief_title": "Efficacy and Safety of Glucosamine Sulfate and Chondroitin Sulfate Combination in Treatment of Knee Osteoarthritis", 
        "completion_date": {
            "#text": "November 2010", 
            "@type": "Actual"
        }, 
        "condition": "Knee Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "detailed_description": {
            "textblock": "The Groups receive treatment for 16 weeks. The study is realized in 16 sites in Brazil."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patient, older than 40 years of age, with knee osteoarthritis, based\n             on clinical and radiological criteria (Kellgren-Lawrence grade 2 - 3), as specified:\n\n               1. Pain on movement of the affected knee for more than 15 days in the previous\n                  month with at least partial relief at rest;\n\n               2. Presence of osteophytes at least 1 mm in radiological imaging;\n\n          -  Knee osteoarthritis symptoms for at least six months prior to randomization.\n\n        Exclusion Criteria:\n\n          -  Concomitant arthropathy that may confuse or interfere with assessing the efficacy or\n             pain;\n\n          -  Patellar disease isolated, with primary symptoms of pain in the anterior knee, in the\n             absence of radiological findings already described;\n\n          -  History of significant injury on collateral ligament, or anterior cruciate, or\n             meniscus of the joint studied, with surgery, or immobilization for at least 3 weeks;\n\n          -  Arthroscopy of the affected knee in last 6 months;\n\n          -  Serum creatinine \u2265 1.8 mg/dL;\n\n          -  Diagnosis of diabetes mellitus;\n\n          -  Presence of any serious disease that could compromise the study, at the investigator\n             discretion;\n\n          -  History of adverse event or allergy to acetaminophen, glucosamine sulfate or\n             chondroitin sulfate;\n\n          -  Inability to understand and report the study questionnaire and the Visual Analogic\n             Scale;\n\n          -  Inability to understand and consent to participate in this clinical study, expressed\n             by signing the Informed Consent (IC);\n\n          -  Woman in pregnancy.\n\n          -  If female of childbearing potential, has a negative urine pregnancy test at Visit 0\n             and do not use, or do not agree to use, for the duration of the study, a medically\n             acceptable form of contraception as determined by the investigator;\n\n          -  Alcohol intake ( > 3 doses/day);\n\n          -  Oral or intramuscular corticosteroids four weeks prior to study entry;\n\n          -  Intra-articular injections with corticosteroids, into the studied knee, within the\n             past three months;\n\n          -  Intra-articular injections in any other joint within the past four weeks;\n\n          -  NSAID users that don\u00b4t respect the washout period. Low-dose aspirin (325 mg or less,\n             once daily) is allowed for cardio-protective benefit;\n\n          -  Intra-articular injections of hyaluronic acid within the past 12 months;\n\n          -  Use of topical analgesic in the joint studied or any other oral analgesic (with the\n             exception of acetaminophen and other NSAID) two weeks prior to randomization;\n\n          -  Implementation of any other medical treatment for osteoarthritis one month prior to\n             study entry;\n\n          -  Participation in last one year of clinical protocols, unless it can be direct benefit\n             to patient;\n\n          -  Use of glucosamine and/or chondroitin sulfate three and six months prior the study\n             entry, respectively;\n\n          -  Initiation of physical therapy two months prior to the study period;\n\n          -  Use of tetracycline and oral anticoagulants;\n\n          -  Use of vitamin D in doses in doses above the recommended;\n\n          -  Patients in alternative therapies;\n\n          -  Allergy to sulfonamides;\n\n          -  Presence of psychiatric disorders that could compromise the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "922", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02010918", 
            "org_study_id": "ACH-ART-03(01/08)"
        }, 
        "intervention": [
            {
                "arm_group_label": "glucosamine sulfate /chondroitin sulfate capsule", 
                "description": "500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.", 
                "intervention_name": "glucosamine sulfate /chondroitin sulfate - capsules", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "glucosamine sulfate /chondroitin sulfate - sachet", 
                "description": "1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.", 
                "intervention_name": "glucosamine sulfate /chondroitin sulfate - sachet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cosamin DS\u00ae", 
                "description": "500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.", 
                "intervention_name": "Cosamin DS\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Knee Osteoarthritis;", 
            "Glucosamine;", 
            "Chondroitin."
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Campinas", 
                    "country": "Brazil", 
                    "state": "S\u00e3o Paulo", 
                    "zip": "13330-260"
                }, 
                "name": "Servi\u00e7o de reumatologia do hospital e maternidade celso pierro da PUC-Campinas"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase III, Multicenter, Randomized, Parallel, Open Label and Comparative Study to Evaluate the Efficacy of 500 mg Glucosamine Sulfate (GS) / 400 mg Chondroitin Sulfate (CS)Capsules and 1500 mg GS / 1200 mg CS Sachet Compared With Cosamin DS\u00ae Capsule in Treatment of Knee Osteoarthritis..", 
        "other_outcome": {
            "measure": "Number of Participants with Serious and Non-Serious Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "baseline, week 16"
        }, 
        "overall_official": {
            "affiliation": "Pontif\u00edcia Universidade Cat\u00f3lica de Campinas, S\u00e3o Paulo, Brazil", 
            "last_name": "Jos\u00e9 R Provenza, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Brazil: National Health Surveillance Agency", 
                "Brazil: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in pain intensity in the affected knee and variation of Lequesne's index and VAS at week 16 .", 
            "safety_issue": "No", 
            "time_frame": "BASELINE, week 16"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02010918"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of Participants with any Decrease in Pain Visual Analogue Scale (VAS)", 
            "safety_issue": "No", 
            "time_frame": "baseline, week 16"
        }, 
        "source": "Ache Laboratorios Farmaceuticos S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ache Laboratorios Farmaceuticos S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}